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Abstract
Introduction: Evidence from a number of open-label, uncontrolled studies has suggested that rituximab may
benefit patients with autoimmune diseases who are refractory to standard-of-care. The objective of this study
was to evaluate the safety and clinical outcomes of rituximab in several standard-of-care-refractory autoimmune
diseases (within rheumatology, nephrology, dermatology and neurology) other than rheumatoid arthritis or
non-Hodgkin’s lymphoma in a real-life clinical setting.
Methods: Patients who received rituximab having shown an inadequate response to standard-of-care had their
safety and clinical outcomes data retrospectively analysed as part of the German Registry of Autoimmune Diseases.
The main outcome measures were safety and clinical response, as judged at the discretion of the investigators.
Results: A total of 370 patients (299 patient-years) with various autoimmune diseases (23.0% with systemic lupus
erythematosus, 15.7% antineutrophil cytoplasmic antibody-associated granulomatous vasculitides, 15.1% multiple
sclerosis and 10.0% pemphigus) from 42 centres received a mean dose of 2,440 mg of rituximab over a median
(range) of 194 (180 to 1,407) days. The overall rate of serious infections was 5.3 per 100 patient-years during
rituximab therapy. Opportunistic infections were infrequent across the whole study population, and mostly
occurred in patients with systemic lupus erythematosus. There were 11 deaths (3.0% of patients) after rituximab
treatment (mean 11.6 months after first infusion, range 0.8 to 31.3 months), with most of the deaths caused by
infections. Overall (n = 293), 13.3% of patients showed no response, 45.1% showed a partial response and 41.6%
showed a complete response. Responses were also reflected by reduced use of glucocorticoids and various
immunosuppressives during rituximab therapy and follow-up compared with before rituximab. Rituximab
generally had a positive effect on patient well-being (physician’s visual analogue scale; mean improvement from
baseline of 12.1 mm).
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Introduction
Research into the pathogenesis of autoimmune diseases
has led to a greater understanding of the function of the
immune cells, and in particular to the role of B cells in
innate and adaptive immunity [1-4]. B cells act as
antigen-presenting cells, are precursors of autoantibody-
producing cells, and produce proinflammatory and anti-
inflammatory cytokines and chemokines that assist the
activation of T cells, all of which may contribute to the
pathogenesis of autoimmune diseases [1,5]. Conse-
quently, interest in B cells as a target in the treatment
of autoimmune disease continues to grow [6].
Preliminary data indicate that B cell depletion may be
effective in autoimmune disease in the areas of rheuma-
tology, nephrology, neurology and dermatology [7].
A greater amount of evidence for the effectiveness of B
cell depletion has been gathered in rheumatoid arthritis
(RA), with recent emerging data indicating that B cell
depletion may also be effective in the treatment of anti-
neutrophil cytoplasmic antibody (ANCA)-associated
granulomatous vasculitis [8- 1 0 ] .R i t u x i m a b ,am o n o c l o -
nal antibody that selectively targets CD20+ B cells and
leads to their depletion, has demonstrated significant
efficacy and a good safety profile in clinical trials
conducted in patients with active RA [11-17]. The long-
term efficacy and safety of rituximab in RA is particu-
larly relevant as many of the autoimmune diseases are
relatively rare, and as such, clinical development of
drugs for these conditions will be less likely.
T h ec u r r e n t l ya v a i l a b l ee v i d e n c ep r o v i d e sac o n f u s i n g
picture as to the benefit:risk profile of rituximab in
various autoimmune diseases, although the bulk of evi-
dence comes from small studies of off-label use [18-55].
There is also a discrepancy between placebo-controlled
clinical trials [56-59] and real-life registry data [60,61],
where patients receiving rituximab mostly had standard
of care (SOC)-refractory disease [62]. Therefore, the
German Registry of Autoimmune Diseases (GRAID) was
established to provide further evidence on the safety and
clinical outcomes of rituximab in patients with autoim-
mune diseases who were enrolled across rheumatology,
dermatology, neurology, and nephrology, and were
mostly SOC-treatment refractory.
Materials and methods
Study design
GRAID was a multicentre, non-interventional, retrospec-
tive study of patients with autoimmune diseases. Patients
who were included in the study had received a regimen
of rituximab that was deemed appropriate by their treat-
ing physician. As patients received rituximab off-label,
the regimens of patients included in the registry varied
across the different autoimmune diseases.
A total of 42 German centres were involved, including
university and other large hospitals as well as private
practices, and included physicians from rheumatology,
haematology, nephrology, neurology, dermatology and
internal medicine specialities. Prior to patient selection,
participating physicians were informed of the inclusion
and exclusion criteria, and received guidance on data
collection. In brief, physicians who had agreed to
p a r t i c i p a t ew e r ea s k e dt op r o v i d ed a t ar e t r o s p e c t i v e l yo n
any patient who had a diagnosis of an autoimmune dis-
ease, excluding RA and non-Hodgkin’s lymphoma (NHL),
who had received rituximab up to and including 31
August 2008. Data were collected retrospectively by the
principal investigators of the centres using a web-based
electronic case report form (eCRF). The eCRF was
designed to only permit entry of the target population,
and was specifically programmed to exclude RA and NHL
patients, and any inconsistencies in data collection. Data
for a selection of 14 diagnoses could be entered. In the
case of non-pre-defined diseases, these were classified as
‘other autoimmune diseases’ (Table 1). The registry was
open for data entry between 20 December 2008 and 31
July 2009.
Ethical approval and approval by the local data protec-
tion agency were obtained by Charite Universitätsmedi-
zin Berlin. Where required, because of local regulations,
local committee approval was obtained by the principal
investigators.
Patients
Patients enrolled on the register were aged ≥ 18 years
with an autoimmune diagnosis other than RA or NHL
and an inadequate response to previous SOC. There was
a requirement that rituximab must have started on or
before 31 August 2008, with the last follow-up before 20
December 2008. There were no restrictions placed on
time to follow-up, although there was a cut-off for data
entry of 31 July 2009. Although informed consent was
not obtained from the participating patients because of
the retrospective nature of this analysis, patients’ data
were protected as follows: all patients’ data were entered
into the register under a pseudonym according to cur-
rent standards, which meant that only the physicians of
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code for participating patients.
Assessments
Clinically adverse events (AEs), including infections,
were recorded throughout the treatment and follow-up
period of the study. The eCRF included supplementary
information on the standardised grading system for the
recording of AEs. The intensity of AEs was graded using
the National Cancer Institute (NCI) Common Terminol-
ogy Criteria for Adverse Events (CTCAE), version 3 or a
Grade 1-5 severity scale. Similarly, serious AEs (SAEs)
were defined as per the International Conference on
Harmonization (ICH) criteria. Infusion-related reactions
(IRRs) were identified by a glossary of MedDRA terms
for AEs occurring during or within 24 hours of an
infusion.
Different assessment tools are used to measure
changes in disease activity for the different autoimmune
diseases; therefore, to enable an approximate compari-
son across the diseases, clinical response was categorised
as complete response, partial response and no response,
as judged at the discretion of the investigators. The use
of certain co-therapies prior to, during and after rituxi-
mab therapy, and patients’ well-being were also assessed.
Patient well-being was estimated using a physician’s
visual analogue scale (VAS), which was measured on a
scale of 0 to 100 mm, with 100 mm indicating
maximum well-being.
Statistical analysis
All patients who were entered into the register were
included in the safety analysis, whereas only patients
with at least one control visit were included in the clini-
cal outcomes analysis. Analysis with standard descriptive
statistics (mean, median) was performed, as well as ana-
lysis of variance (ANOVA) testing for differences
between centres and disease types. Poisson regression
was used to investigate the relationship between infec-
tion rates and disease state. To determine any differ-
ences in distribution patterns of response across the
different diseases, responses of patients for individual
diseases were analysed using the chi-squared test and a
row mean difference test.
Results
Patient disposition and treatment
A total of 370 patients with a diagnosis of an autoim-
mune condition other than RA or NHL and treated with
rituximab provided a total of 299 patient-years of obser-
vation in this study population (Table 1; further detail of
the follow-up period for each diagnosis is provided in the
Additional file 1). The most common diagnosis was SLE
(23.0% of patients), with the least represented disorder
Table 1 Patient demographics and mean doses of rituximab received by patients with various autoimmune diseases
Diagnosis Patients,
n (%)
Total observation
time, patient-years
Mean (SD) rituximab
dose, mg
Total 370 299 2,440 (1,295)
Arthritis (non-RA)/ankylosing spondylitis/psoriatic arthritis 6 (1.6) 3.8 2,333 (816)
Autoimmune haemolytic anaemia 3 (0.8) 1.6 2,233 (204)
Autoimmune thrombocytopenia 10 (2.7) 6.5 2,602 (1,047)
Glomerulonephritis 9 (2.4) 7.0 2,150 (1,660)
Cryoglobulinaemic vasculitis 5 (1.4) 4.1 2,576 (971)
Wegener’s granulomatosis/microscopic polyangiitis 58 (15.7) 61.4 3,008 (1,524)
Multiple sclerosis/neuromyelitis optica 56 (15.1) 48.3 2,679 (1,252)
Myasthenia gravis 5 (1.4) 2.7 1,890 (1,107)
Pemphigus 37 (10.0) 22.7 1,755 (1,163)
Sjögren’s syndrome 6 (1.6) 4.3 2,271 (995)
Polydermatomyositis 26 (7.0) 23.4 2,634 (1,810)
Systemic lupus erythematosus 85 (23.0) 66.8 2,331 (1,033)
Vasculitis 13 (3.5) 9.5 2,277 (1,168)
Overlap syndromes: mixed connective tissue disease 19 (5.1) 16.3 2,550 (1,031)
Others
a 32 (8.6) 20.8 2,079 (1,224)
RA, rheumatoid arthritis; SD, standard deviation.
aOther autoimmune diseases included: Felty syndrome (n = 1); antiphospholipid syndrome (n = 1); chronic inflammatory demyelinating polyneuropathy (CIDP)
(n = 3); anti-myelin associated glycoprotein associated with CIDP (n = 1); anti-Scl70-positive systemic sclerosis with myositis (n = 1); thrombotic thrombocytopenic
purpura (n = 2); epidermolysis bullosa acquisita (n = 3); bullous pemphigoid (n = 1); mucous membrane pemphigoid (n = 1); uveitis (n = 1); Behçet disease
(n = 1); systemic sclerosis (n = 1); systemic sclerosis with CREST syndrome (n = 1); diffuse cutaneous sclerosis (n = 1); common variable immunodeficiency (n = 1);
Castleman’s disease (n = 1); human immunodeficiency virus and myopathy (n = 1); Still’s disease (n = 1); Crohn’s disease (n = 1); Lambert-Eaton myasthenic
syndrome (n = 1); autoimmune neuropathy (n = 1); stiff-person syndrome (n = 1); unspecified vasculitis (n = 1); anti-Hu positive encephalopathy of the brain
stem (n = 1); acquired factor VIII haemophilia (n = 1); sarcoidosis (n = 1); diagnosis not specified (n = 1).
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patients).
A total of 86% of patients received > 1 infusion with
rituximab. Of the total rituximab infusions received
across all diagnoses, the majority of patients received
two (39.2% of patients) or four (34.1%) infusions, fol-
lowed by those who received only one infusion of rituxi-
mab (13.5%); three (0.8%) patients received > 8 infusions
of rituximab (further detail of the number of rituximab
infusions is provided in Additional file 1). Most patients
(77.6%) received one course of rituximab with 18.6% of
patients having received two courses. The mean dose of
rituximab received by the patients was 2,440 mg/patient
over a median period of 194 (180 to 1,407) days.
Patients with ANCA-associated granulomatous vasculitis
received the highest doses of rituximab (mean dose/
patient 3,008 mg) and most conditions were treated
with > 2,000 mg of rituximab per patient during this
study (Table 1). Only patients with myasthenia gravis or
pemphigus received less than 2,000 mg over the study
period.
Safety
The majority of patients (87.8%) had no documented
infection. During treatment with rituximab, there was
an overall rate of infection of 18.1 per 100 patient-years.
The patient groups with the highest rate of infection
were those with glomerulonephritis (43 per 100 patient-
years) and myasthenia gravis (72.8 per 100 patient-
years) (Figure 1). However, these patient groups were
rather small and, therefore, statistical analysis (ANOVA)
did not identify a disease-related higher risk for
infections.
The majority of infections were mild (3.8% of the
overall population) or moderate (3.2%) in severity,
although 3.7% of patients had severe infections. An ana-
lysis of the distribution of infections showed that the
majority of clinically relevant infections occurred within
seven months of the first rituximab infusion (Figure 2).
The majority of the infections were bacterial (n = 26),
with the remainder being of viral (n = 9), fungal (n =4 )
or unknown (n = 5) origin. Interestingly, only very few
patients had more than one infection during the study:
there were two different infections in three patients and
three different infections in two patients. Thus, in most
cases only one infection was recorded during the obser-
vation period of the study.
For serious infections, the overall rate was 5.3 per 100
patient-years during rituximab therapy. Rates of serious
infections were generally low across all the conditions
studied (Figure 1). The greatest rate of serious infections
was reported by patients with myasthenia gravis (36.4
per 100 patient-years). The high rate of infections and
serious infections in patients with myasthenia gravis was
Figure 1 Rates of infection and serious infections in patients with various autoimmune diseases who received rituximab.T h e
frequencies depicted are based on different sizes of the patient groups (see Table 1). ANOVA testing for heterogeneity between the patient
groups did not provide significant differences between the patient groups. AIHA, autoimmune haemolytic anaemia; AITP, autoimmune
thrombocytopenia; AS, ankylosing spondylitis; MCTD, mixed connective tissue disease; MP, microscopic polyangiitis; NMO, neuromyelitis optica;
PA, psoriatic arthritis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; WG, ANCA-associated granulomatous vasculitis.
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observation period (2.7 patient-years). However, there
was no statistically (ANOVA) significant relationship
between infection rates and any diagnosis; although,
there was a significant relationship between higher
doses of rituximab and a reduced rate of infections
(Poisson regression model).
Opportunistic infections were infrequent across the
whole study population, and mostly occurred in patients
with SLE. There were five opportunistic infections
recorded in patients with SLE. Bacterial infections, con-
sidered and recorded by the individual participating
physicians as opportunistic infections, included a gastro-
intestinal infection caused by Salmonella typhimurium
(n = 1), meningococcal meningitis (n =1 )a n dListeria
meningitis (n = 1). The remaining two patients with SLE
had outbreaks of oesophageal candidiasis and Herpes
zoster infection. There were also two other cases of
Herpes zoster reactivation, one each in patients with
Wegener’s granulomatosis and pemphigus.
During treatment with rituximab, overall, there were
22 (5.9%) IRRs, 15 (4.1%) allergic reactions, 9 (2.4%)
severe IRRs leading to discontinuation of therapy and 21
(5.7%) undifferentiated IRRs. When IRRs, allergic reac-
tions and severe IRRs were distributed by autoimmune
condition, no more than 2% of patients were affected,
with no significantly enhanced rate or type of reaction
in any particular disease (P =0 . 6 5 ,c h i - s q u a r e dt e s t )
(Figure 3).
Of the 370 patients, there have been 11 deaths (3.0%
of patients) reported following treatment with rituximab
(Table 2). Patients with ANCA-associated granuloma-
tous vasculitis were the group most affected (four
deaths), followed by those with polydermatomyositis
(three deaths). Infection was the major cause of death,
which was the cause in seven cases. The timing of the
11 deaths after rituximab therapy (mean 11.6 months)
ranged between 0.8 and 31.3 months after the first infu-
sion of rituximab. Notably, the study protocol required
documentation within six months after the last rituxi-
mab therapy. Thus, five deaths occurred in this period;
for the remaining six deaths, these occurred outside the
protocol-specified period of six months and, therefore,
the data of this patient group are less certain. Patients
(n = 7) with a short interval between rituximab infusion
and death (< 7 months) had highly active, uncontrolled
disease and received rituximab as a final option during
intensive care therapy. Four of the deaths occurred
more than 11 months after rituximab therapy. Two
patients with ANCA-associated granulomatous vasculitis
died 13.8 and 11.1 months after the last infusion of
rituximab (31.3 and 12.7 months, respectively, after the
first infusion) and two patients with polydermatomyosi-
tis died at 12.7 and 14.2 months following first and only
Figure 2 Distribution of total number of infections over time following rituximab infusion in patients with autoimmune diseases.
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SLE and MS, no deaths were reported.
In terms of co-therapy (Table 3), it needs to be
emphasised that prior to rituximab therapy almost all
patients received immunosuppressives (98.1%) together
with a high frequency of glucocorticoids, intravenous
immunoglobulin (Ig) (17.0%) and plasmapheresis
(13.8%), consistent with a very refractory patient popula-
tion. In addition, the frequency of usage of almost all of
these therapies substantially decreased during therapy
with rituximab, with the exception of prednisolone use
which was comparable before and during rituximab
(68.9% versus 66.1%). After rituximab therapy, the pro-
portion of patients using other therapies remained lower
than use prior to rituximab, although the use of
immunosuppressives showed a trend towards greater
use compared with during rituximab (Table 3).
Clinical outcomes
Of the 370 patients, 293 patients had at least one con-
trol visit and, therefore, were included in the clinical
Table 2 Number and cause of deaths according to
autoimmune disease diagnosis
Cause of death Diagnosis Total, n
Infection Wegener’s granulomatosis/microscopic
polyangiitis (n =2 )
Myasthenia gravis (n =1 )
Polydermatomyositis (n =2 )
Mixed connective tissue disease (n =1 )
Other (n =1 )
7
Other, unspecified Wegener’s granulomatosis/microscopic
polyangiitis (n =1 )
Multiple sclerosis/neuromyelitis optica
(n =1 )
Polydermatomyositis (n =1 )
3
Infection plus
other event
Wegener’s granulomatosis/microscopic
polyangiitis (n =1 )
1
Figure 3 Proportion of patients with various autoimmune diseases who had infusion-related reactions (IRRs), allergic reactions and
withdrawals because of severe IRRs during rituximab therapy. AIHA, autoimmune haemolytic anaemia; AITP, autoimmune
thrombocytopenia; AS, ankylosing spondylitis; MCTD, mixed connective tissue disease; MP, microscopic polyangiitis; NMO, neuromyelitis optica;
PA, psoriatic arthritis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; WG, ANCA-associated granulomatous vasculitis.
Table 3 Overall comparison of the frequency of patients
with autoimmune diseases
Proportion (%) of patients receiving
co-therapies
Before
rituximab
During
rituximab
After rituximab
during follow-up
a
Immunosuppressives 98.1 41.2 78.6
Prednisolone 68.9 66.1 58.9
with glucocorticoid
bolus therapy
17.0 1.25 1.6
Methylprednisolone 25.4 13.2 4.3
Methotrexate 22.1 6.9 8.9
Cyclophosphamide 36.2 8.15 3.2
Azathioprine 38.1 11.9 10.8
Mycophenolate
mofetil
27.6 15.0 17.8
Intravenous Ig 17.0 3.4 5.1
Plasmapheresis 13.8 3.4 0.8
Other
immunosuppressives
16.0 5.3 5.4
Overall comparison of the frequency of patients with autoimmune diseases
receiving at least one administration of different types of therapies before,
during and after rituximab therapy. Note, that certain immunosuppressive
drugs were substantially different between individual diseases and only
frequencies above 10% have been considered for this comparison.
aFollow-up was as defined and recorded by the investigating physician.
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with autoimmune diseases had been classified as having
no response to rituximab (Figure 4). In the overall study
population independent of the underlying disease, 39
patients (13.3%) showed no response, 132 (45.1%)
showed a partial response and 122 (41.6%) showed a
complete response. There was a trend towards patients
with no response having received a lower mean dose of
rituximab compared with those with a partial or com-
plete response (Table 4). When separated out into the
various autoimmune diseases, all patients with Sjögren’s
syndrome, autoimmune thrombocytopenia, glomerulo-
nephritis, cryoglobulinaemic vasculitis and myasthenia
gravis were shown to have a response to rituximab
(partial or complete) (Figure 4). However, these patient
groups were small and bias can therefore not be
excluded. When comparing the response rates between
different patient groups, there was no significant differ-
ence using strict statistical methods (row mean scores
differ, P = 0.26), including chi-squared test (P = 0.0872).
Rituximab generally had a positive effect on patient
well-being. Overall, there was an improvement from
baseline in the estimation of patients’ well-being (physi-
cian’s VAS; mean improvement of 12.1 mm) following
rituximab (Figure 5). Patients with pemphigus had the
greatest improvement in well-being (from 33.8 to 75.0
mm). Patients with polydermatomyositis, vasculitis,
glomerulonephritis and cryoglobulinaemic vasculitis
showed slight reductions in VAS scores following rituxi-
m a b ,w h e r e a sp a t i e n t sw i t hm y a s t h e n i ag r a v i ss h o w e d
no change in VAS scores.
Discussion
This study was designed to assess the safety and clinical
outcomes of rituximab in refractory patients with var-
ious autoimmune diseases in a real-life clinical setting.
Generally, rituximab was well tolerated across a number
of autoimmune diseases and patients tended to have at
least a partial response to therapy. Furthermore, rituxi-
mab was generally shown toh a v eap o s i t i v ee f f e c to n
patient well-being, although it should be noted that this
conclusion is based on a subjective outcome measure
and so should be considered with caution.
In the current analysis across autoimmune diseases,
the overall rate of infections and serious infections com-
pares well with analyses of rituximab in RA [17] and
SLE [63]. There are few studies that provide controlled
trial data in other autoimmune diseases; however, in the
Figure 4 Distribution of global response rates (full, partial versus no response) in patients with various autoimmune diseases who
received rituximab, as reported by the treating physician over a median (range) of 194 (180 to 1,407) days according to the
underlying diagnosis. AIHA, autoimmune haemolytic anaemia; AITP, autoimmune thrombocytopenia; AS, ankylosing spondylitis; MP,
microscopic polyangiitis; NMO, neuromyelitis optica; PA, psoriatic arthritis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; WG, ANCA-
associated granulomatous vasculitis.
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sclerosis was treated with rituximab or a placebo, a
greater proportion of patients in the placebo group had
serious infectious events than those receiving rituximab
(5.7% versus 2.9%) [56]. The strict exclusion criteria
employed in this study restricted entry of high-risk
patients, and so this study does not truly reflect what
might be expected in a real-life clinical setting. Overall,
the current evidence would suggest that serious infec-
tions occur in a small proportion of patients with auto-
immune diseases during rituximab therapy. In contrast,
two controlled studies in SLE (EXPLORER) and lupus
nephritis (LUNAR) have shown slightly elevated serious
infection rates of 9.5% [59] and 16.4% [58], respectively,
during rituximab therapy in combination with SOC
(including mycophenolate mofetil (in EXPLORER and
LUNAR), and methotrexate and azathioprine (in
EXPLORER)) and high-dose corticosteroids, which
might indicate that the regimens studied may not have
been appropriate for these populations. An elevated ser-
ious infection rate was also reported in the rituximab
group of the RITUXIVAS study, although, these patients
with ANCA-associated vasculitis also received
cyclophosphamide and high-dose corticosteroids as part
of the regimen, and no differences in the rates were
shown as compared with the control group, which
received a cyclophosphamide-based regimen (18% for
each regimen) [20]. In these three studies, serious infec-
tion rates were similar or elevated in the control groups
compared with the rituximab regimens. Therefore, and
in addition to, a potential relationship with underlying
disease, concomitant immunomodulating therapies can-
not be ruled out as a cause [20,58,59]. In particular, cor-
ticosteroids have an important additional effect on T
cells and have been shown to be an important predis-
posing factor for infections [64]. Moreover, reduced IgG
levels at baseline have been identified as risk factor for
infections in RA [17] for which insufficient data were
available in the registry to search for their role in modu-
lating infectious risks and so further studies are needed.
Data on Ig levels and B cell depletion were lacking from
this current analysis, and therefore, these data are
needed in subsequent registry studies.
Of interest is that the infection (serious and non-ser-
ious) rates over time remained stable with multiple
courses of rituximab in RA [17]. In addition, it has
Table 4 Doses of rituximab stratified by response in patients with different autoimmune diseases
Mean (SD) dose, mg
Diagnosis No
response
Partial
response
Complete response
Total n = 39
1,990 (798)
n = 132
2,683 (1,408)
n = 122
2,528 (1,346)
Arthritis (non-RA)/ankylosing spondylitis/psoriatic arthritis n =1
2,000 (-)
n =4
2,500 (1,000)
-
Autoimmune haemolytic anaemia n =1
2,320 (-)
n =1
2,000 (-)
n =1
2,380 (-)
Autoimmune thrombocytopenia - n =5
2,248 (1,321)
n =5
2,956 (641)
Glomerulonephritis - n =6
1,625 (826)
n =2
4,100 (2,970)
Cryoglobulinaemic vasculitis - n =3
2,960 (1,154)
n =1
2,000 (-)
Wegener’s granulomatosis/microscopic polyangiitis n =4
2,193 (561)
n =2 9
3,474 (1,642)
n =2 2
2,586 (1,384)
Multiple sclerosis/neuromyelitis optica n =9
2,022 (570)
n =3 1
2,678 (903)
n =1 4
3,157 (1,992)
Myasthenia gravis - n =2
2,500 (707)
n =2
1,225 (1,662)
Pemphigus n =2
1,500 (707)
n =1 3
1,770 (899)
n =2 2
1,769 (1,352)
Sjögren’s syndrome - n =2
2,312 (441)
n =2
3,000 (1,414)
Polydermatomyositis n =5
1,700 (447)
n =6
3,900 (3,209)
n =1 0
2,818 (1,003)
Systemic lupus erythematosus n =1 5
2,121 (1,099)
n =2 7
2,440 (1,119)
n =3 7
2,499 (926)
Vasculitis n =2
1,500 (707)
n =3
2,200 (346)
n =4
3,000 (1,155)
RA, rheumatoid arthritis; SD, standard deviation.
Tony et al. Arthritis Research & Therapy 2011, 13:R75
http://arthritis-research.com/content/13/3/R75
Page 8 of 14been reported that retreatment with rituximab based
on treatment to target DAS28 remission in patients
with RA compared with an ‘on demand’ approach
resulted in better disease control with comparable
safety profiles [65]. Furthermore, retreatment with
rituximab at a fixed interval of six months provided
greater improvements in disease control at one year
with a serious infection rate similar to that in patients
with RA who received a single course [15,66]. These
data might suggest that control over disease activity
m a yb ec l o s e l yr e l a t e dt os a f e t ya n dt h er i s ko fi n f e c -
tions. With the suggestion from the current clinical
outcomes data that responses may be improved with
greater doses of rituximab in patients with various
autoimmune diseases, a stable safety profile over time
will provide physicians with the confidence to pre-
scribe multiple courses of rituximab for patients with
autoimmune conditions. Although most of the com-
plex systemic diseases reported here may require
higher doses per se,d o s e - f i n d i n g ss t u d ies for rituximab
within the individual diagnoses are still lacking and
preclude any far-reaching conclusions.
A significant relationship between higher doses and a
reduced rate of infections (Poisson regression model)
was also demonstrated in this analysis. However, it can-
not be excluded that infections led to discontinuation of
therapy and resulted in lower treatment doses. Indeed,
the majority of clinically relevant infections occurred
within seven months of the first rituximab infusion,
likely reflecting that severe infections led to discontinua-
tion of rituximab. Therefore, a selection bias of patients
initially developing infections remains possible. Alterna-
tively, control of disease activity by successful rituximab
therapy may have led to reduced disease activity and
reduced subsequent infections as suggested by fixed-
dosing intervals of rituximab in RA [65]. The overall
safety data of this registry do not indicate that certain
diseases may have a higher risk for any adverse event,
including a higher propensity of infections. This conclu-
sion can be further substantiated by the observation that
during rituximab therapy the lowest frequencies of cer-
tain co-therapies were registered (Table 3), which
reflects the overall clinical effect by this B cell directed
therapy as well as that these co-therapies likely do not
Figure 5 Mean changes from baseline in patients’ well-being over a median (range) of 194 (180 to 1,407) days during rituximab
therapy in patients with various autoimmune diseases, as measured using the visual analogue scale (VAS; 0 to 100 mm) rated by the
treating physician. VAS scores were not assessed in patients with mixed connective tissue disease or ‘other’ autoimmune diseases. AIHA,
autoimmune haemolytic anaemia; AITP, autoimmune thrombocytopenia; AS, ankylosing spondylitis; MP, microscopic polyangiitis; NMO,
neuromyelitis optica; PA, psoriatic arthritis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; WG, ANCA-associated granulomatous
vasculitis.
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Page 9 of 14substantially confound the safety database. The increase
of various therapeutic modalities after rituximab therapy
is likely related to increased disease activity or when
insufficient response to rituximab required new
treatments.
Although a direct comparison cannot be made
between the safety analysis of rituximab in patients with
RA [17] and the current study for several reasons (het-
erogeneous patient populations, different dosing regi-
mens and different study periods), it appears from the
long-term analysis in RA that IRRs diminish over time;
therefore, it would not be unreasonable to expect that
the rate of IRRs over time in various autoimmune dis-
eases might decrease with each course of rituximab.
However, caution should be taken in interpreting these
data as patients with more severe IRRs may discontinue
rituximab and, therefore, provide a distorted impression.
In addition, IRRs were defined in this analysis as events
that occurred during or within 24 hours of an infusion,
which does not capture those that may have occurred
after one week, for example; therefore, the data recorded
in this registry may represent an under-reporting of the
level of IRRs. Fortunately, the vast experience with
rituximab in RA and NHL has led to effective techni-
ques in managing these infusion-related complications.
In the RA clinical trial programme for rituximab,
there were few deaths that occurred in patients in the
rituximab groups [12,17]. The number of deaths across
autoimmune diseases appears to be relatively high con-
sidering the short observation period of the current
study, even though the proportion of deaths is no
greater than that reported in the Spanish registry; how-
ever, the follow-up period in the Spanish registry was
considerably longer than that of the current study [60].
In placebo-controlled trials investigating the efficacy and
safety of rituximab in autoimmune diseases for one year
or more, the proportion of deaths appears low (< 3%)
[56-59]. The discrepancy in safety profiles between the
real-life, observational studies and randomised, con-
trolled trials may be explained by consideration of the
study entry criteria. In real-life studies, the entry criteria
are more ‘relaxed’ than in randomised, controlled trials,
which often result in higher-risk patients being included;
consequently, outcomes such as mortality rates can be
elevated in real-life studies. Overall, no specific pattern
emerged from this analysis of GRAID in relation to the
type of infection leading to death, prior therapies, age,
gender and dosing of rituximab. The deaths predomi-
nantly occurred in a short amount of time following
rituximab therapy; however, patients had previously
received intensive immunosuppressive therapy and had
uncontrolled severe disease, both of which would
enhance the risks of severe infection and life-threatening
complications [62,67-71]. In a study of patients with
refractory RA [12], an infection was complicated by an
existing heart condition during rituximab therapy, which
led to the death of a patient, thus illustrating the diffi-
c u l t yi nc l e a r l yr e l a t i n gc a u s eo fd e a t hi nt h ec o n t e x to f
severe confounding risk factors. In the recent RITUXI-
VAS study, a relatively high number of deaths occurred
early in the course of therapy (median time to death: 81
days) [8]; however, overall 18% of patients died in the
control group (cyclophosphamide), which compared
well with 18% in the treatment arm (cyclophosphamide
+ rituximab). Together with the data of the current
study with the highest death rates among patients with
ANCA-associated granulmatous vasculitides, the recent
trial results of RITUXIVAS indicate the challenges of
this disease and suggest that previous and co-therapies
as well as comorbidities play a substantial role in this
complication. Patients in this and the RAVE study also
had an elevated number of malignancies in a short time
period [8,9], which was not observed in the current
GRAID analysis. In these challenging and often difficult
to treat conditions, therapeutic options are limited and
physicians are often required to weigh up the benefit:
risk ratio of newer therapies off-label.
Response to rituximab in patients with refractory RA
h a sb e e np r o v e ni nan u m b e rof well-designed clinical
studies [11-16]. The current analysis and previous ana-
lyses of registry data [60,61] provide an indication that
the effectiveness of rituximab may not be limited solely
to the treatment of RA. In addition, our data are very
much consistent with reported open-label experiences
[21,22,25,26,30-33,36-38,40,43,44,72]. However, the
interpretation of these data is limited without the
inclusion of a control group, and some placebo-con-
trolled studies of rituximab in specific autoimmune
diseases failed to provide co n c l u s i v ee v i d e n c ea st oi t s
benefit [9,56-59]. The current study differs from the
lupus studies (LUNAR [58] and EXPLORER [59]) in
that data were collected from otherwise refractory
patients while both controlled studies included patients
who were stable on SOC at study entry and received
rituximab plus SOC in the active group compared with
SOC in the control group. Further endorsement of the
benefit of rituximab in a refractory population has
been provided by the RAVE study [9]. In a subgroup
of patients with ANCA-associated granulomatous vas-
culitis who had relapsed with SOC (in particular,
cyclophosphamide), rituximab was shown to be super-
ior to SOC (P = 0.01), whereas in the overall popula-
tion that included newly diagnosed disease, there was
no significant difference shown between rituximab and
the control. Therefore, the bulk of evidence would sug-
gest that treatment of autoimmune diseases, other than
RA, with rituximab represents a therapeutic option to
consider.
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Page 10 of 14An additional interesting analysis of the GRAID data
revealed that there were no significant differences in the
distribution patterns for complete, partial and no
response across the different autoimmune diseases.
However, some patient groups were very small and
given the lack of prospective use of validated outcome
measures, it cannot be excluded that certain diagnoses
have distinct response profiles.
With the continued gathering of evidence from
patients with autoimmune diseases treated with rituxi-
mab in the real-life setting, supplemented with evidence
from well-controlled trials, the picture should become
clearer as to which autoimmune diseases and which
populations, based on disease stage and previous treat-
ments, are suitable for treatment with rituximab.
Although it is very important that data are gathered on
patients who might usually be excluded from clinical
trials, there are several limitations to studies based on
registry data. In general, retrospective, observational
studies lack the structure and control groups of a rando-
mised, controlled trial, and the inclusion of heteroge-
neous patient populations and treatment regimens make
comparison with other data difficult. In this particular
study, the data collected depended on the interpretation
of the individual, participating physicians, and so there
may be a lack of consistency in defining certain events
and responses. Small patient numbers in any study
reduce the power for observing a difference among
groups. In the current study, small patient numbers for
certain autoimmune diseases may have skewed the
results, and subsequent interpretation, which may have
precluded the identification of different safety profiles as
well as different response profiles compared with the
overall population. Finally, incomplete patient records
and different follow-up observation periods of individual
patients may also add to the limitation in these types of
study. In particular, this retrospective analysis is limited
by the data that have been recorded and captured within
the database; therefore, the reporting of IRRs (as men-
tioned above), the way response was recorded (that is, at
the physicians discretion), incomplete data on comor-
bidities and the lack of long-term follow-up safety data
all limit the interpretation of these data.
Conclusions
These data in a real-life clinical setting indicate that
rituximab is frequently used as an off-label therapy, and
suggest that rituximab may be an effective and well-tol-
erated therapy in a number of treatment-refractory
autoimmune diseases, in line with results from the
French and Spanish registries of patients with various
autoimmune diseases [60,61]. Further randomised,
controlled studies in addition to collecting further regis-
t r yd a t aa r ew a r r a n t e dt oe v a l u a t et h eu s eo fr i t u x i m a b
fully in these conditions, and to confirm the legitimacy
of the results from this current analysis. Registry data,
in particular, are extremely valuable since they provide
information on patient populations usually excluded
from clinical trials. Since certain therapies may provide
benefit to otherwise refractory patients, it is an ethical
obligation to search and evaluate potential therapeutic
options for patients in urgent need.
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